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Abstract
Background: Posttraumatic Stress Disorder (PTSD) is a commonly occurring mental illness. There are multiple
treatments for PTSD that have similar effectiveness, but these treatments differ substantially in other ways. It is
desirable to have well-informed patients involved in treatment choices. A patient decision aid (PtDA) is one method
to achieve this goal. This manuscript describes the rationale and development of a patient decision aid (PtDA)
designed for patients with PTSD.
Methods: We conducted an informational needs assessment of veterans (n = 19) to obtain their baseline
information needs prior to the development of the PtDA. We also conducted a literature review of effective PTSD
treatments, and we calculated respective effective sizes. A PtDA prototype was developed according to the
guidelines from the International Patient Decision Aid Standards. These standards guided our development of both
content and format for the PtDA. In accordance with the standards, we gathered feedback from patients (n = 20)
and providers (n = 7) to further refine the PtDA. The information obtained from patients and the literature review
was used to develop a decision aid for patients with PTSD.
Results: Patients with PTSD reported a strong preference to receive information about treatment options. They
expressed interest in also learning about PTSD symptoms. The patients preferred information presented in a
booklet format. From our literature review several treatments emerged as effective for PTSD: Cognitive Therapy,
Exposure Therapy, Eye Movement Desensitization Therapy, Selective Serotonin Reuptake Inhibitors, venlafaxine,
and risperidone.
Conclusion: It appears that the criteria set forth to develop decision aids can effectively be applied to PTSD. The
resultant PTSD patient decision aid is a booklet that describes the causes, symptoms, and treatments for PTSD.
Future work will examine the effects of use of the PTSD decision aid in clinical practice.
Trial registration: Clinicaltrials.gov identifier NCT00908440. Registered May 20, 2009.
Keywords: Shared decision making, Patient decision aid, Posttraumatic stress disorder, Patient-centered care

Background
Posttraumatic stress disorder (PTSD)

Posttraumatic stress disorder (PTSD) is a common psychological disorder that can occur after exposure to a
traumatic event such as military combat, sexual/physical
assault, natural disasters, or vehicular crashes [1].
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Symptoms of PTSD fall into four categories. These include intrusion symptoms (e.g., intrusive thoughts,
nightmares and flashbacks), avoidance (i.e., avoiding
thoughts, feelings, and people/places related to the
traumatic event), negative alterations in mood (inability
to remember, distorted cognitions, guilt), and arousal
symptoms (e.g., irritability, trouble sleeping, hyperarousal, and startle reflex) [1]. Individuals with PTSD
often experience financial, interpersonal, occupational,
legal, and/or housing problems [2]. PTSD can be a
severe and disabling condition.
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PTSD prevalence

Shared decision making

According to the National Comorbidity Survey–Replication, almost 7 % of adults in the United States (US) experience PTSD at some point in their lifetime [3]. The
presence of PTSD is even more common in populations
such as military combat veterans. According to the National Vietnam Veterans Readjustment study, 30 % of
Vietnam veterans developed PTSD at some point following the war [4]. The Rand Corporation’s Center for Military Health Policy Research estimated that the current
prevalence of PTSD is 14 % among veterans of the recent wars in Iraq and Afghanistan [5].

Current concepts of quality advocate not only for the use of
effective treatments for a disorder, but also that the treatments be patient-centered [21]. Patient-centered care is a
multidimensional construct that includes patient education
and incorporating patient preferences into clinical care
[22]. Shared decision making has been advocated as one
method of achieving patient- centered care [23]. The term
shared decision making refers to the communication that
takes place with patients who wish to be involved in their
health care decisions. Shared decision making is a method
that addresses one of the Institute of Medicine core aims
for improvement, patient-centered care [21]. Research suggests that shared decision making is associated with positive
patient outcomes, such as increased knowledge, satisfaction
with treatment, and improvement in symptoms [23].

PTSD treatment

PTSD treatment in clinical practice has been informed by
several clinical practice guidelines that have been developed over the past decade [6–11]. Although the guidelines
differ slightly in their recommendations, there is considerable consensus. Several psychotherapies appear effective
(i.e., Cognitive Therapy, Exposure Therapy, and Eye Movement Desensitization and Reprocessing Therapy). Cognitive Therapies involve helping patients to restructure their
maladaptive thoughts or thoughts that maintain their
PTSD symptoms. The rationale is that such restructuring
will help patients replace thoughts associated with fear
with less distressing ones [12]. Exposure-based treatments
involve having patients repeatedly re-experience memories
of their traumatic event. The rationale is that this structured exposure to traumatic memories will help patients
gain control of their emotional responses to their trauma
and thus experience less fear [13]. Eye Movement
Desensitization and Reprocessing involves having patients
revisit their trauma memories while simultaneously performing saccadic eye movements. The rationale underlying
Eye Movement Desensitization and Reprocessing Therapy
is that coupling eye movements with revisiting of trauma
memories will help patients gain control over their emotional responses to their trauma [14].
There is also consensus among most practice guidelines regarding medication [6–11]. The guidelines generally agree that the selective serotonin reuptake inhibitors
(e.g., sertraline, fluoxetine, paroxetine) are an effective
treatment. This class of medications affects the neurotransmitter serotonin and has strong evidence from randomized controlled trials supporting its use [15–18].
Similarly, selective norepinephrine reuptake inhibitors
such as venlafaxine have been recommended by practice
guidelines. This group of medications affects both serotonin and norepinephrine and has been shown to be effective in randomized controlled trials [19].
Although there is considerable evidence that a variety
of treatments are effective for treating PTSD, there is no
single best treatment. However, few head to head studies
with adequate sample size have been conducted [20].

Patient decision aids

Shared decision making may include use of a patient decision aid (PtDA), which is a condition-specific tool designed to inform patients about treatment decisions.
PtDAs can take the form of booklets, DVDs, videos,
interactive computer programs, or websites [23]. PtDAs
are specifically designed to help patients understand and
choose between two or more relevant treatment options.
Effective PtDAs do this by providing patients with detailed, high-quality, and balanced information about each
option’s possible benefits and potential risks. The PtDA
can help patients understand that the selection of a particular option is dependent on their informed preferences towards these benefits and risks.
The Cochrane Collaboration has systematically reviewed
over 115 randomized clinical trials of PtDAs for use in
screening, prevention, and medical-surgical care. The review confirms that well-designed PtDAs help patients to
participate in making informed choices that are consistent
with their values [23]. Moreover, PtDAs were better than
treatment as usual when it came to increasing patients
knowledge and satisfaction with treatment [23].
Recent research has examined the use of PtDAs for
mental health disorders [24, 25]. In a study of patients
with schizophrenia a decision aid resulted in enhanced
patient knowledge of treatments [24]. Similarly a study
conducted in patients with major depressive disorder
found that patients’ use of PtDAs was associated with increased involvement in decision-making and satisfaction
with mental health care.
In this paper, we describe the development of a PtDA for
PTSD. At the time of this study, no PtDA for PTSD was
available. PTSD is condition well-suited for a PtDA in that
there are several effective treatments [20, 26, 27]. PTSD
treatments do vary substantially in other ways. For example, a patient with PTSD could reasonably choose psychotherapy requiring a weekly visit with a therapist or
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medication therapy involving daily ingestion of a tablet at
home. We conducted a randomized trial comparing the
outcomes of patients who received the PtDa with patients
who recieved usual care. We found that the decision aid
led to greater knowledge about PTSD and less conflict
about their choice of tretament, as well as increased likelihood of receiving evidence-based treatment and improved
PTSD outcomes. In this paper, we describe the development of a PtDA for PTSD [28]. Below, we describe the
three step process that we used to develop the PtDA: 1) informational needs assessment, 2) review of literature for
descriptions of PTSD and corresponding effective treatments, and 3) prototype development.

Methods
General approach

This project was approved by the Dartmouth College
Committee for the Protection of Human Subjects and
registered on clinicaltrials.gov on May 20, 2009. Written
informed consent was obtained from all participants.
We were guided by the International Patient Decision
Aid Standards (IPDAS) collaboration criteria for both
content and development of the decision aid for PTSD
[23]. Briefly, IPDAS specifies that any PtDA should contain the following: natural course of condition without
therapy, procedures for each treatment option, potential
benefits and disadvantages for each option, and probabilities of benefits and side effects/harms. IPDAS criteria for development of a decision aid are as follows:
based on current scientific evidence, conflicts disclosed,
and field tests with patients and practitioners to ensure
that the decision aid is acceptable and understood. The
development of this new decision aid involved three
steps that resulted in specifying the information content
and developing the prototype.
Step 1: Informational needs assessment

We recruited participants (n = 19) diagnosed with PTSD at
the White River Junction Veterans Affairs Medical Center
(VAMC). Participants could have a new or long standing
diagnosis of PTSD. Participants were not excluded due to
the presence or absence of any co-morbid medical or psychiatric diagnosis. A research assistant conducted a 60-min
semi-structured interview with each participant. Participants were asked to report their opinions regarding (a)
information they wished to know about PTSD, (b) information they felt they needed in order to make a therapeutic choice, and (c) their favored presentation format for
information. We continued to recruit participants with
PTSD to interview until consistent themes emerged among
the participating veterans’ responses (i.e., theoretical saturation where no new themes emerge from participants and
concepts in a theory are well-developed) [29].
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Step 2: Review of literature for description of PTSD and
its effective treatments

No definitive review of PTSD treatments was available.
Therefore, we conducted a comprehensive review and
analysis of effective treatments for PTSD. We searched
the relevant literature using PubMed, Medline, PILOTS,
Psycinfo, and the Cochrane Collaboration’s databases
from 1980 (the date of establishment of the Diagnostic
and Statistical Manual criteria for PTSD) until January 1,
2013 [31]. The search terms “post-traumatic stress disorders,” “posttraumatic stress disorder,” “PTSD,” “combat
disorders,” and “stress disorders, post-traumatic” were
used [30]. The search results were limited to articles
indexed as clinical trials or those that included the terms
“treatment trial,” “randomized trial,” or “controlled trial”
in their title or abstract. In order to locate additional
sources, the authors systematically reviewed the references cited in all included studies as well as previous review articles or meta-analyses.
We considered only studies that (1) randomized participants to one or more active treatments and to a control group; (2) involved only adult participants who all
met standard PTSD diagnostic criteria as set forth in the
third, revised third, or fourth editions of the Diagnostic
and Statistical Manual of Mental Disorders; and (3) included pre-treatment and post-treatment measures of
PTSD symptoms [32–34]. Treatment trials of similar
types of therapy were pooled into treatment groupings.
Treatments were included in the decision aid only if: (1)
they differed statistically from the control group; and (2)
had been studied in 100 or more participants in all
pooled trials (including the total number in the treatment and control groups).
We calculated an effect size, compared to control
group levels, for each type of treatment [34]. For manuscripts that provided data regarding response rates, we
also collected PTSD response rate. Treatment response
was defined as no longer meeting PTSD diagnosis [35–
37]. As most studies did not include the categorical data,
we imputed missing values for treatment response based
on the continuous outcome data. These response rates
were then used to develop the graphical displays used in
the PtDA.
For manuscripts that reported only a continuous
measure of outcome, we transformed the between
groups treatment effect size into a percentage response
rate that approximated PTSD treatment response. This
allowed us to derive a weighted, pooled, average response rate for each particular treatment grouping.
We reviewed several of the leading references in the
field of PTSD in order to develop a description of PTSD
and description of the different PTSD symptoms and
treatments [7, 31]. The descriptions were modified as
needed to reflect a desired seventh grade reading level.
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Step 3: Prototype development

We elected to pursue development of a decision aid in
booklet format based on the feedback from the participants with PTSD, and we utilized an iterative design
process for the drafts of the booklets. For each draft that
was constructed, the booklet was reviewed by a committee that included experts in the field of patient decision
aids and experts in the field of PTSD. The committee
assessed whether the informational content met the
International Patient Decision Aid Standards, met the
informational needs of patients, and was consistent with
the published literature.
After six iterative reviews cycles, an initial version was
agreed upon. Patients with PTSD and providers who
treated such patients were asked to provide feedback
about the initial version. The focus of this field testing
was to obtain reports about the clarity of the PtDA
prototype. Participants (n = 20) with PTSD seeking treatment from the White River Junction VAMC were recruited and individually given the draft of the PtDA
decision aid. They were asked for feedback regarding
clarity of presentation, ability to hold attention, and
overall balance. These participants were different from
the initial group of veterans who participated in the
needs assessment. All participants were diagnosed with
PTSD and had been stable in treatment in the mental
health clinic for at least two years. The participants were
first allowed to review the draft version of the decision
aid, and then reviewed each page with research assistant
using a semi-structured questioning format.
In addition, psychiatrists and psychologists (n = 7)
working in the PTSD treatment clinic were shown the
decision aid and their feedback was sought. The providers were working in a specialized PTSD clinic. They
were well-versed in all of the evidence-based treatments
described in the PtDA. The provider group as a whole
had extensive experience with the described PTSD treatments. Again, the feedback was collected through the
same review process by a research assistant who conducted an interview guided by a semi-structured interview tool.
Feedback from both participant and providers was incorporated into a second version of the PtDA. An independent panel, who had not been involved in the
previous development or review steps, reviewed the final
version of the PtDA. Their feedback was collected and
incorporated into the final decision aid version.

Results and discussion
Step 1: Information needs assessment

Nineteen participants (16 men, 3 women) completed the
needs assessment interview. All participants were recruited from the mental health clinic at the White River
Junction VAMC. Ages ranged from 28–66 years, with a
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mean of 48 years. There was considerable variability in
the time they had been involved in treatment for PTSD
ranging from one month to 34 years, with a mean of
5.6 years.
When veterans were asked: “What do you want to
know about PTSD?” the majority (59 %, n = 11) wanted
to know about PTSD symptoms or its long-term effects
on health. For example, one veteran stated, “I don’t even
know what the doctor means by PTSD…which of my
problems are PTSD?” Another participant asked, “What
I want to know is what this stress thing is doing to my
heart.” Other issues that emerged with less frequency
were: knowing that PTSD is treatable (21 %, n = 4); realizing that “it’s not my fault” (11 %, n = 2); knowing that
PTSD is a mental illness (11 %, n = 2); and understanding that PTSD is a disorder that affects many people
(11 %, n = 2).
Almost all participants (95 %, n = 18) also spontaneously reported that they wanted to know what treatments were available for PTSD and wanted a description
of those treatments. One participant summed up many
others thoughts in saying, “Skip all the crap, just tell me
what works.” A majority (68 %, n = 13) also wanted to
know about specific treatment efficacy. “They keep saying take such and such medication for PTSD, but how
well does it work.” Other themes that emerged with less
frequency included side effects (21 %, n = 4), availability
of treatments (10.5 %, n = 2), and coverage of treatments
by health insurance (10.5 %, n = 2).
When participants were asked: “How would you best
like the information presented to you,” most wanted information presented in a booklet (47 %, n = 9) or presented verbally by a counselor or doctor (31 %, n = 6). “I
want something that I can touch and hold,” as an example was reported by one participant. A smaller percentage of participants (21 %, n = 4) wanted information
presented on the internet or via email. Other formats
that emerged were video (10.5 %, n = 2), and verbal communication with veteran (5 %, n = 1). Please note three
partisipants equally preferred two formats thus the total
exceeds 19. There were no trends in the preferences
based on either patient age or era of military service.
Step 2: Review of literature for description of PTSD and
its effective treatments

One hundred and twelve manuscripts examining 137
different treatment trials met the inclusion criteria for
this review and were included in the analysis. Treatments included individual psychotherapy, group psychotherapy, pharmacotherapy, and other novel treatments
for PTSD.
Several treatments showed a statistically significant
improvement in PTSD symptoms compared to the control condition. The treatments that were both more
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effective than control and studied in more than 100 participants included psychotherapies (Cognitive Therapy,
Exposure Therapy, and Eye Movement Desensitization
and Reprocessing Therapy), and medications (selective
serotonin reuptake inhibitors, risperidone, and venlafaxine). As these treatments showed clear evidence of effectiveness, they were selected for presentation in the
draft PtDA.
A full description of the literature and meta-analysis
can be found in Watts et. al 2012 [20].

Step 3: Prototype development

The initial draft of the PtDA was twenty-one pages long.
The first page was a cover page; the second page listed
the goals of the PtDA, and then the PtDA itself consisted of five sections that provided a description of
PTSD as well as information about its effective treatments. Specifically, information was provided about individual psychotherapy for PTSD, medications for PTSD,
and finally a summary about the different types of PTSD
treatment.
We received feedback on the draft from 20 participants currently receiving treatment at the White River
Junction VA. In addition, we received feedback from
four psychiatrists and three psychologists. None of the
participants or providers had been involved in the development of the draft. Participant and provider feedback
was generally positive; respondents reported that the decision aid was “easy to follow,” and “easy to read and
understand.” “The book seemed OK, it was pretty easy
and helpful,” report one participant. “Another reported,
“I think this would help a new veteran with PTSD pick a
therapy.” The primary concerns voiced by both participants and providers were that the graphics used to illustrate relative efficacy were difficult to understand (i.e.,
Fig. 1). “I didn’t get the smiley faces,” was a common
comment. In addition, multiple small changes were

Fig. 1 Visual depiction of treatment efficacy
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recommended. These typically involved clarification and
simplification of the language.

Conclusions
We developed a PtDA designed for participants with PTSD
that reflected their informational needs and current knowledge about effective treatments (see Additional file 1 for
complete version of the decision aid). This decision aid
was developed using the established standards for the
development of a patient decision aid [28]. Early feedback
suggested that the PtDA was understandable to participants with PTSD and providers who treat PTSD. This suggests that an acceptable decision aid can be developed for
participants with PTSD by using the standards in the field.
Based on the informational needs assessment, it was
clear that participants most wanted to know about
PTSD and the effective treatments for PTSD. This is
consistent with previous research that suggests that patients want to be more involved in their mental health
care (when compared to care for physical illnesses) [38].
The development of a PtDA for PTSD provides a first
step in the goal of providing more patient-centered care.
Some limitations should be noted. First, the treatments
described in this PtDA were limited to those that
emerged as effective from review of the published literature. While these treatments are likely to be effective for
PTSD, some participants may not have access to all the
treatments described. Second, as this PtDA was developed using feedback from participants receiving care at
a VA hospital, its applicability to other populations with
PTSD is unclear. It is possible that veterans with PTSD
have unique preference for information. Similarly, we received considerable feedback from participants who had
already been treated for PTSD. It is possible that treatment naive patients have different needs and preferences. Third, we sampled a small number of participants
and providers from a single PTSD clinic for feedback regarding the decision aid. It is possible this group of
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participants and providers may differ in important ways
from the general population of patients with PTSD and
providers who treat PTSD. In addition, we asked providers or participants to provide feedback about the
PtDA rather than use it. It remains to be seen whether
providers or patients will embrace such a tool. Likely
substantial barriers would be faced to get providers to
use the PTDA in typical practice. Future research should
focus on better understanding these barriers.
The presence of the decision aid does not guarantee
that care for patients with PTSD will be patient centered. We know little about how or if this tool will be
used; however, its availability provides a possible route
towards patient centered care which we think will be of
great interest to clinicians and researchers.
Although the development of the PtDA is a necessary
first step, many questions remain about the use and effectiveness of the PtDA for PTSD. Our randomized trial
found that the decision aid led to great knowledge and
better clinical outcomes [28]. Future research is needed
to further evaluate the effect on patients’ knowledge and
decision making. Similarly, we have only limited information regarding what effect the PtDA for PTSD will
have on the processes of care (i.e. type of treatment received) and PTSD symptom outcomes. We have little
understanding about how the PtDA could be incorporated into the care process for patients with PTSD. For
example, when is the best time to give the PtDA to the
patient, and whether it is important for the provider to
review the PtDA with the patient? Similarly we currently
have little knowledge about how patients would use the
PtDA. Will patients review the entire 21 page booklet,
or will they focus only on those pages describing treatments they are most interested in having? If these important questions can be successfully addressed, there is
potential for the PTSD decision aid to facilitate patient
centered care for patients with PTSD.

Additional file
Additional file 1: Complete version of the decision aid. (PDF 176 kb)

Abbreviations
DVD: digital video disk; N: number; PtDA: patient decision aid;
PTSD: Posttraumatic Stress Disorder; US: United States; VAMC: Veterans Affairs
Medical Centers.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BVW: Participated in the study design, co-lead the decision aid development coordinated the study, and drafted the manuscript. PPS: Participated in the study
design, co-lead the decision aid development, and edited the manuscript. MZ:
Conducted all study interviews and focus groups and conducted qualitative
analysis of material. HLT: Participated in study design, assisted with decision aid

Page 6 of 7

development, assisted with qualitative analysis, and assisted with editing the
manuscript. All authors reviewed and approved the final manuscript.
Acknowledgements
The study was funded by the Veterans Affairs Health Services Research and
Development Grant # 07-266-1: Washington DC. We acknowledge Patricia
Stender, who assisted with participant recruitment, and TeChieh Chen who
edited the manuscript.
The views expressed in this article do not necessarily represent the views of
the Department of Veterans Affairs or of the United States government.
Author details
1
VA National Center for Patient Safety, White River Junction, VT, USA. 2White
River Junction VA Medical Center, White River Junction, VT, USA. 3Geisel
School of Medicine at Dartmouth College, Hanover, NH, USA. 4The
Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, USA.
5
National Center for PTSD, White River Junction, VT, USA.
Received: 11 March 2015 Accepted: 21 January 2016

References
1. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders. 5th ed. Washington, D.C: American Psychiatric Association;
2013.
2. Schnurr PP, Lunney CA, Bovin MJ, Marx BP. Posttraumatic stress disorder
and quality of life: extension of findings to veterans of the wars in Iraq and
Afghanistan. Clin Psychol Rev. 2009;29:727–35.
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime
prevalence and age-of-onset distributions of DSM-IV disorders in the national
comorbidity survey replication. Arch Gen Psychiatry. 2005;62:593–602.
4. Kulka RA, Shlenger WE, Fairbank JA, Hough RL, Jordan BK, Marmar CR, et al.
Trauma and the Vietnam war generation: report of the findings from the
National Vietnam Veterans’ Readjustment Study. New York: Brunner/Mazel;
1990.
5. Vaughn CA, Schell TL, Tomielian T. Prevalence of mental health problems
among Iraq and Afghanistan veterans who have not received VA services.
Psychiatr Serv. 2014;65:833–5.
6. Australian Centre for Posttraumatic Mental Health. Australian guidelines for
the treatment of adults with acute stress disorder and posttraumatic stress
disorder. Melbourne: ACPMH; 2007.
7. Foa EB, Keane TM, Friedman MJ, Cohen JA. Effective treatments for PTSD.
2nd ed. New York: Guilford; 2008.
8. VA/DoD Clinical Practice Guideline Working Group. Management of
post-traumatic stress. Washington, DC: Veterans Health Administration,
Department of Veterans Affairs and Health Affairs; Department of
Defense; Office of Quality and Performance; 2010. Publication 10Q-CPG/
PTSD-03.
9. American Psychiatric Association. Practice guidelines for the treatment of
patients with acute stress disorder and posttraumatic stress disorder.
Arlington: American Psychiatric Association; 2004.
10. National Collaborating Centre for Mental Health. Post-traumatic stress
disorder: the management of PTSD in adults and children in primary and
secondary care. London: Gaskell and the British Psychological Society; 2005.
11. Institute of Medicine. Treatment of posttraumatic stress disorder: an
assessment of the evidence. Washington, DC: National Academies Press;
2008.
12. Resick PA, Schnicke MK. Cognitive processing therapy for sexual assault
survivors. J Consult Clin Psychol. 1992;60:748–56.
13. Foa EB, Rothbaum BO, Riggs DS, Murdock TB. Treatment of posttraumatic
stress disorder in rape victims: a comparison between cognitive-behavioral
procedures and counseling. J Consult Clin Psychol. 1991;59:715–23.
14. Shapiro F. Eye movement desensitization and reprocessing: basic principles,
protocols and procedures. New York: Guilford Press; 2001.
15. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, et al. Efficacy
and safety of sertraline treatment of posttraumatic stress disorder: a
randomized controlled trial. JAMA. 2000;283:1837–44.
16. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM.
Multicenter, double-blind comparison of sertraline and placebo in the
treatment of posttraumatic stress disorder. Arch Gen Psychiatry.
2001;58:485–92.

Watts et al. BMC Psychiatry (2016) 16:21

17. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of
paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled
study. Am J Psychiatry. 2001;158:1982–8.
18. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD.
Paroxetine in the treatment of chronic posttraumatic stress disorder: results
of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry.
2001;62:860–8.
19. Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, et al.
Treatment of posttraumatic stress disorder with venlafaxine extended
release: a six month randomized, controlled trial. Arch Gen Psychiatry. 2006;
63:1158–65.
20. Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Metaanalysis of the efficacy of treatments for posttraumatic stress disorder. J Clin
Psych. 2013;74:541–50.
21. Institute of Medicine. Crossing the quality chasm. Washington, DC: National
Academy Press; 2001.
22. The President’s New Freedom Commission on Mental Health. Achieving the
promise: transforming mental health care in America. Washington, DC:
Substance Abuse and Mental Health Service Administration; 2003.
23. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision
aids for people facing health treatment or screening decisions. Cochrane
Database Syst Rev. 2014;1:CD001431.
24. Hamann J, Langer B, Winkler V, Busch R, Cohen R, Leucht S, et al. Shared
decision making for in-patients with schizophrenia. Acta Psychiatr Scand.
2006;114:265–73.
25. Loh A, Simon D, Wills CE, Kriston L, Niebling W, Harter M. The effects of a
shared decision making intervention in primary care of depression: a
cluster-randomized controlled trial. Patient Educ Couns. 2007;67:324–32.
26. Benish SG, Imel ZE, Wampold BE. The relative efficacy of bona fide
psychotherapies for treating post-traumatic stress disorder: a meta-analysis
of direct comparisons. Clin Psychol Rev. 2008;28:746–58.
27. Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional metaanalysis of psychotherapy for PTSD. Am J Psychiatry. 2005;162:214–27.
28. Watts BV, Schnurr PP, Zayed M, Young-Xu Y, Stender P, Llewellyn-Thomas H.
A randomized controlled clinical trail of a patient decision aid for PTSD.
Psych Serv. 2015;66(2):149–54.
29. Guest G, Bunce A, Johnson L. How many interviews are enough? An
experiment with data saturation and variability. Field Methods.
2006;18:59–82.
30. National Center for Posttraumatic Stress Disorder [homepage on the
internet]. Available at http://ptsd.va.gov; accessed January 15, 2015.
31. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders. 3rd ed. Washington, D.C: American Psychiatric Association;
1980.
32. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders. 3rd ed. revised. Washington, D.C: American Psychiatric
Association; 1987.
33. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders. 4th ed. revised. Washington, D.C: American Psychiatric
Association; 1994.
34. Cohen J. Statistical power analysis for the behavioral sciences. New Jersey:
Lawrence Erlbaum Associates; 1988.
35. Bryant RA, Moulds ML, Guthrie RM, Dang ST, Nixon RD. Imaginal exposure
alone and imaginal exposure with cognitive restructuring in treatment of
posttraumatic stress disorder. J Consult Clin Psychol. 2003;71:706–12.
36. Lee C, Gavriel H, Drummond P, Richards J, Greenwald R. Treatment of PTSD:
stress inoculation training with prolonged exposure compared to EMDR.
J Clin Psychol. 2002;58:1071–89.
37. Schnurr PP, Friedman MJ, Engel CC, Foa EB, Shea MT, Chow BK, et al.
Cognitive behavioral therapy for posttraumatic stress disorder in women: a
randomized controlled trial. JAMA. 2007;297:820–30.
38. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Do patients with
schizophrenia wish to be involved in decisions about their medical
treatment? Am J Psychiatr. 2005;162:2382–4.

Page 7 of 7

Submit your next manuscript to BioMed Central
and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit

